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ABSTRACT
Background: Despite the large number of surveys, there are not 
any validated biomarkers for SLE disease activity till now. This 
study aimed to evaluate the relationship between serum level of 
IL-2 in patients with SLE and disease activity in comparison with 
control group.
Materials and Methods: In this case-control study, 73 patients 
with lupus and 73 healthy subjects referred to the rheumatology 
clinic of 5 Azar Hospital in Gorgan (North of Iran).They were 
studied via convenience sampling during 2011-2012. Blood 
samples were taken from both groups and serum levels of 
interleukin -2 measured by Avi Bion Human IL-2 ELISA kit. Serum 
Level of IL-2 greater than 15 pg/ml defined positive and lesser 
than this amount defined negative. Disease activity evaluated 
with SLE disease activity index. Score greater than or equal to 
three or four defined as active disease. Data analysis conducted 
by SPSS software (version 16) and by using descriptive statistics 
and statistical tests. 
Results: Serum level of IL-2 was positive in 45.2% of sample 
studied and negative in 54.8% in case group, while in control 
group, serum level of IL-2 only in 11% of sample studied was 
positive and in 89% was negative. Statistical analysis indicated a 
significant relationship between serum level of IL-2 and the SLE 
disease activity index (p=0.025).
Conclusion: This study showed the relationship between serum 
levels of IL-2 and disease activity, so this biomarker can be used 
as a clinical indicator for assessing disease activity in patients 
with SLE. 
InTROduCTIOn 
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune 
disease which affects almost every systems in the body with 
different degrees of severity disease [1]. In this disease, organs 
and cells damage by auto-antibodies binding tissue and immune 
complexes [2]. It is characterized by an imbalance in the cytokine 
network [3] and lupus T and natural killer (NK) cells fail to produce 
enough IL-2 and transforming growth factor (TGF-β) to induce and 
maintain regulatory CD4+ and CD8+ T cells that result in continuous 
production of auto-antibodies and immune complexes. In chronic 
inflammation, accumulation of growth factors and products of 
chronic oxidation lead to irreversible tissue damage such as fibrosis/ 
sclerosis in glomeruli, arteries, brain, lungs, and other tissues [2]. 
Alcocer-Varela indicated that in SLE, T cells produce decreased 
amounts of IL-2 that is very obvious in cells of patients with active 
type of disease [4]. Campen also indicated a  strong relationship 
between serum levels of IL-2R and clinical and laboratory indicators 
of disease activity in patients with lupus and rheumatoid arthritis 
that correlated with disease activity better than the erythrocyte 
sedimentation rate (ESR) and it may be a reliable serologic indicator 
of disease activity in inflammatory diseases characterized by immune 
system activation [5]. Due to the great heterogeneity of the disease 
and complex and difficult process to validate individual biomarkers, 
there are very limited numbers of consensus biomarkers to aid the 
treatment in SLE [6].
Despite the large number of surveys, there are not any validated 
biomarkers for SLE disease activity up to now. However, the vast 
majority of studies were not validated biomarkers abnormalities. 
Identification of these biomarkers may make it possible to assess 
disease activity and response to therapy in patients with SLE [7] 
and it can enhance the clinical management of patients and prepare 
more effective therapies for diseases that their treatment is very 
difficult [6]. Approving the relationship between serum levels of IL-2 
and disease activity index can help produce novel drugs, more 
effective control of disease and reduce the disease implications in 
patient with SLE, so this study aimed to evaluate the relationship 
between serum level of IL-2 in patients with SLE and disease activity 
in comparison with control group.
MATeRIAlS And MeThOdS 
In this case-control study, 146 patients referred to the rheumatology 
clinic of 5 Azar Hospital in Gorgan (North of Iran).They were studied via 
convenience sampling during 2011 to 2012. Seventy three patients 
with the definite diagnosis of SLE based on clinical manifestations 
and laboratory tests and having greater than or equal to four from 
eleven criteria [2] classified to case group and 73 healthy subjects 
matched by age and sex entered to the study as control group. At 
the start of the study, all the patients in case group were under the 
treatment, however, to minimize the effect of treatment on serum 
level of IL-2 in case group, the patients did not receive any treatment 
48 hours before the blood samples were taken. 
In this study, medical history was taken and physical examination 
conducted by rheumatologist and laboratory tests asked if needed 
and patients with following conditions excluded from the study: 
history of thyroid disease (Graves’ disease and Hashimoto’s 
thyroiditis), atopic dermatitis and psoriasis, asthma and idiopathic 
hypereosinophilic syndrome (HES), end stage renal disease 
(ESRD) and hemodialysis, malignancy, repetitive abortion and 
early pregnancy loss, congestive heart failure (CHF) and recent 
myocardial infarction (MI), liver disease and autoimmune diseases 
such as rheumatoid arthritis (RA) and Behcet disease, chronic 
headache, brain injury and cerebrovascular accident (CVA), 
Journal of Clinical and Diagnostic Research. 2014 Jul, Vol-8(7): MC16-MC18 17
www.jcdr.net Sima Sedighi et al., IL-2 & Disease Activity in SLE
 
Keywords: Adults, Disease activity, ELISA, Interleukin-2, Systematic lupus erythematosus
schizophrenia, infectious diseases especially tuberculosis (TB), human 
immunodeficiency virus (HIV) and herpes simplex, pancreatitis, 
diabetes and recent consumption of Amiodarone, non steroidal 
anti-inflammatory drugs (NSAIDs) and immunosuppressive drugs 
such as Cyclophosphamide, Cyclosporine, Tacrolimus, Syrulymus, 
Thalidomide and Mycophenolate Mofetil, organ transplantation and 
corticosteroids use within the last 48 hours [8-16].
After obtaining informed consent, 10 cc blood sample was 
taken from all participants and the checklist consists of age, sex, 
height, weight, duration of disease and patients` treatment was 
completed. 
Serum levels of IL-2 was measured in pg/ml at a 450 nm wavelength 
by means of Avi Bion Human IL-2 ELISA Kit made in Orgenium 
Company in Fenland. The Accuracy and sensitivity of used kits were 
15 pg/ml and 95%, respectively. 
In laboratory, initially, 1: 100 dilution performed by 100 micro liter 
of ELISA diluents solution for all samples, then they were mixed by 
shaker and incubated at room temperature (25°C) for two hours 
and washed by appropriate buffer solution. After that, Avidin-
Horseradish Peroxidase (Avidin-HRP) conjugated was added to 
samples prepared and incubated at room temperature for one hour. 
After rewashing them by appropriate buffer solution, Tetramethyl­
benzidine (TMB) had been added and incubated for 30 min at room 
temperature in the dark environment. Finally, one molar phosphoric 
acid solution in proportion of one to 50 added and the serum level of 
IL-2 was measured in pg/ml at a 450 nm wavelength. Serum Level 
of IL-2 which was greater than 15 pg /ml was considered positive 
and less than this amount considered negative. 
In this study, SLE disease activity index (SLEDAI-2000) was used to 
assess the disease activity and the score greater than or equal to 
three or four defined active disease [8]. Change in SLE-DAI score 
greater than or equal to four points indicates mild flare, change in 
SLEDAI score of five to nine points indicates moderate flare and 
Change in SLEDAI score greater than or equal to 10 points indicates 
severe flare [17].
Finally, statistical analysis conducted by SPSS software (version 16) 
and descriptive statistics (frequency, mean and standard deviation) 
and chi-square test and student t-Test were used. A p-value less 
than 0.05 was considered statistically significant. 
ReSulTS 
In this case control study, 97.3% of subjects (n=71) were female 
and 2.7% (n=2) were male in both groups. The mean and standard 
deviation for age, weight and height in case and control group are 
shown in [Table/Fig-1]. Patients treated with Prednisone (82.2%), 
Hydroxychloroquine Sulfate (80.8%), Methoterexate (MTX) (34.2%) 
and Azathioprine (16.4%). Eighteen patients in case group (24.7%) 
had active disease according to score of SLE-DAI and the mean 
of disease duration were 38.98 ± 4.62 months in case group. 
SLE disease activity index (SLE-DAI) were mild in 75.3% (n=55), 
moderate in 15.1% (n=11) and severe in 9.6% (n=7) of patients.
Case group Control group
Age (year) 34.04 ± 1.40 34.45 ±1.35
Weight (kg) 62.63±1.35 62.26±1.30
Height (cm) 161.19±2.87 160.91±2.80
[Table/Fig-1]: Mean and standard deviation in case and control group for age, 
weight and height
In this study, serum level of IL-2 was positive in 45.2% (n=33) of 
sample studied and negative in 54.8% (n=40) in case group, while 
in control group, it only in 11% of sample studied (n=8) was positive 
and in 89% (n=65) was negative. Analysis with Chi-square test 
showed a significant relationship between serum level of IL-2 and 
the SLE disease activity index (DAI) (p=0.025). Moreover, a significant 
relationship between serum level of IL-2 and disease duration were 
seen (p=0.008). A strong relationship was seen between serum 
level of IL-2 and consumption of Prednisone, too (p=0.017).
Moreover, there was a significant relationship between serum level 
of IL-2 and patients age in case group (p=0.059), Moreover, analysis 
with t-Test showed a significant relationship between serum level of 
IL-2 and patients` height in case group (p=0.035). Analysis in control 
group showed the strong relationship between serum level of IL-2 
and subjects height (p=0.039) while any significant relationship were 
not seen between serum level of IL-2 and patients` weight in the two 
groups. 
dISCuSSIOn 
Deficiency in IL-2 synthesis and activity has been proven in animal 
models and in humans with SLE [18] and IL-2R may be assumed 
as a reliable serologic indicator of disease activity in inflammatory 
diseases characterized by immune system activation [5]. IL-2 
production of T-lymphocytes was in low levels in the majority of the 
patients with SLE before the administration of treatment [3] and was 
high in 50% of patients with active disease [19], while in this study, 
serum level of IL-2 was positive in 42.5% of the patients; this may 
be due to the patients treatment before the study which it could not 
be stopped based on legal and ethical regulations related to the 
patients. El-Shafey found that levels of soluble IL-2R alpha were 
significantly higher in patients with SLE compared to the control 
group (p<0.001) [20] and significantly higher in active than in inactive 
patients (p<0.05) [21]. Results of the present study also showed 
the significant association between serum level of IL-2 and the SLE 
disease activity.  
Deregulation of IL-2 and IL-6 production take place during ageing 
process. Production of IL-2 is regulated in healthy people with the 
age of 60–70; however, a lower level of IL-2 was seen in the sera of 
not healthy people [22]. Pietschmann (2003) showed an increased 
proportion of T cells that were positive for interferon-γ, interleukin-2, 
4, 10 and 13, in comparison of elderly to young women [23]. Present 
study showed the significant relationship between age of patients 
and serum level of IL-2. It seems that aging is one of the effective 
factors on IL-2 production. 
Level of IL-2R elevated before the exacerbation of disease (p<0.02) 
and fell following the treatment (p< 0.05) and it was higher even in 
the absence of disease activity or during minor disease symptoms 
(p<0.01) and its serial measurement can be a sensitive indicator for 
prediction of disease exacerbations in patient with SLE [24]. While, 
Salaffi indicated that after 24 weeks of treatment with Methotrexate, 
Sulphasalazine and Dehydroxychloroquine, no differences were 
seen in serum sIL-2R in comparison with basal levels and the 
measurement of sIL-2R is not a useful marker for response to 
treatment with second line drugs in RA [25]. Findings of the present 
study showed a significant relationship between duration of disease 
and serum level of IL-2. Although the most studies demonstrated 
that serum soluble IL-2 levels can be used for evaluation of treatment 
in rheumatoid disorders, but it can be changed in patients received 
different drugs, further evaluations are needed.
Studies showed that levels of sIL-2R were higher among patients 
with active RA than healthy controls and decreased significantly 
following to corticosteroid pulse therapy [26] and Cyclosporine-A 
therapy in RA could significantly reduce circulating concentrations 
of IL-6 and sIL-2R [27] and measurement of circulating sIL-2R, p55 
and IL-6 may be useful for the evaluation of disease activity and 
response to therapy in RA disease [28]. Results of present study 
also showed a significant relationship between serum level of IL-2 
and consumption of Prednisone. 
According to the results of current study, there was a significant 
relationship between serum level of IL-2 and patients height in case 
and control group, while any relationship between serum level of IL-2 
and patients weight were not seen. Chaiamnuay indicated that an 
increased BMI is not associated with disease activity in patients with 
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SLE [29]. Garcia-Gonzalez also demonstrated that no association 
between leptin levels and Mex-SLEDAI score, age, duration of 
disease, or Prednisone doses were seen in patients with lupus [30]. 
Despite extensive search, any relevant articles could not have been 
found to approve these findings, so further research should be done 
to investigate the impact of weight and height of patients with SLE 
on serum level of IL-2. 
COnCluSIOn
Due to the relationship between serum level of IL-2 and disease 
activity in patients with SLE in this region, this biomarker can be 
used as a clinical indicator for disease activity in patients with SLE. 
Moreover, factors like age, duration of disease and height may have 
impact on serum level of IL-2 by unknown mechanisms, so these 
factors should be concerned in patient assessment and treatment. 
lIMITATIOnS
Complete elimination of patients` drugs was not possible due to 
respect for patients` rights and financial support in order to study 
large number of subjects. 
ReCOMMendATIOnS
Due to effects of age, height and duration of disease on serum level 
of IL-2, a study on large number of subjects with wide range of 
these variables is recommended. 
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